Natural History of Predominantly Classic, Minimally Classic, and Occult Subgroups in Exudative Age-related Macular Degeneration

Ophthalmology

Volumn 116, Issue 10, 2009, Pages 1901-1907

  Shah, Ankoor R ^a   Del Priore, Lucian V ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER COAGULATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; EXUDATES AND TRANSUDATES; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULAR DEGENERATION; TIME FACTORS; VISION DISORDERS; VISUAL ACUITY;

EID: 70349469705     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.03.055     Document Type: Article

References (24)

1. Bressler N.M., Bressler S.B., and Fine S.L. Age-related macular degeneration. Surv Ophthalmol 32 (1988) 375-413
2. West S.K. Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol Rev 22 (2000) 64-70
3. Green W.R., and Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 100 (1993) 1519-1535
4. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
5. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
6. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
7. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
8. Shah A.R., and Del Priore L.V. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol 143 (2007) 83-89
9. DiLoreto Jr. D.A., Bressler N.M., Bressler S.B., and Schachat A.P. Use of best and final visual acuity outcomes in ophthalmological research. Arch Ophthalmol 121 (2003) 1586-1590
10. Thomson D. VA testing in optometric practice. Part 2: Newer chart designs. Optom Today May (2005) 22-24. http://www.otmagazine.co.uk/articles/docs/fdaa91e06ebe44f10bc2ccef8d892e17_thomson20050506.pdf Accessed January 15, 2009
11. Boyer D.S., Antoszyk A.N., Awh C.C., et al., MARINA Study Group. Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114 (2007) 246-252
12. Kaiser P.K., Brown D.M., Zhang K., et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144 (2007) 850-857
13. Bressler S.B., Pieramici D.J., Koester J.M., and Bressler N.M. Natural history of minimally classic subfoveal choroidal neovascular lesions in the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) investigation: outcomes potentially relevant to management-TAP report no. 6. Arch Ophthalmol 122 (2004) 325-329
14. Schneider U., Gelisken F., and Inhoffen W. Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. Acta Ophthalmol Scand 83 (2005) 141-147
15. Pieramici D.J., Bressler S.B., Koester J.M., and Bressler N.M. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4. Arch Ophthalmol 124 (2006) 660-664
16. Polito A., Isola M., Lanzetta P., et al. The natural history of occult choroidal neovascularisation associated with age-related macular degeneration: a systematic review. Ann Acad Med Singapore 35 (2006) 145-150
17. Bressler S.B., Silva J.C., Bressler N.M., et al. Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 110 (1992) 827-832
18. Grossniklaus H.E., Brooks Jr. H.L., Sippy B.D., and Liu P. Retinal translocation and photodynamic therapy for age-related macular degeneration with classic choroidal neovascularization: a clinicopathologic case report. Retina 22 (2002) 818-824
19. Lafaut B.A., Bartz-Schmidt K.U., Vanden Broecke C., et al. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 84 (2000) 239-243
20. Sarks S.H. Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol 60 (1976) 324-341
21. Sarks S., Cherepanoff S., Killingsworth M., and Sarks J. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci 48 (2007) 968-977
22. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 109 (1991) 1220-1231
23. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
24. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (2003) 407-418